The estimated Net Worth of Jeffrey M Leiden is at least $364 Milion dollars as of 30 August 2024. Jeffrey Leiden owns over 3,784 units of Vertex Pharmaceuticals stock worth over $4,744,552 and over the last 21 years he sold VRTX stock worth over $340,637,339. In addition, he makes $18,790,000 as Executive Chairman of the Board at Vertex Pharmaceuticals.
Jeffrey has made over 59 trades of the Vertex Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 3,784 units of VRTX stock worth $1,888,216 on 30 August 2024.
The largest trade he's ever made was selling 216,624 units of Vertex Pharmaceuticals stock on 19 July 2017 worth over $34,867,799. On average, Jeffrey trades about 28,248 units every 70 days since 2004. As of 30 August 2024 he still owns at least 9,994 units of Vertex Pharmaceuticals stock.
You can see the complete history of Jeffrey Leiden stock trades at the bottom of the page.
Dr. Jeffrey M. Leiden M.D. Ph.D. has been appointed as Executive Chairman of the Board of the company. Effective April 01, 2020. and he is President, Chief Executive Officer of Vertex Pharmaceuticals Incorporated. Effective April 01, 2020. He has held the positions of Chief Executive Officer and President since February 2012 after joining us as CEO Designee in December 2011. He has been a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden serves as a director of Quest Diagnostics Inc., a medical diagnostics company, and Massachusetts Mutual Life Insurance Company, an insurance company. Dr. Leiden was a director and the non-executive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
As the Executive Chairman of the Board of Vertex Pharmaceuticals, the total compensation of Jeffrey Leiden at Vertex Pharmaceuticals is $18,790,000. There are no executives at Vertex Pharmaceuticals getting paid more.
Jeffrey Leiden is 64, he's been the Executive Chairman of the Board of Vertex Pharmaceuticals since 2020. There are 3 older and 21 younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals, Inc. is William Young, 75, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON, MA, 02210.
Over the last 21 years, insiders at Vertex Pharmaceuticals have traded over $934,925,905 worth of Vertex Pharmaceuticals stock and bought 308,652 units worth $12,298,449 . The most active insiders traders include Lloyd Carney, Jeffrey M Leiden a Joshua S Boger. On average, Vertex Pharmaceuticals executives and independent directors trade stock every 5 days with the average trade being worth of $4,747,875. The most recent stock trade was executed by Jeffrey M Leiden on 30 August 2024, trading 3,784 units of VRTX stock currently worth $1,888,216.
Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Vertex Pharmaceuticals executives and other stock owners filed with the SEC include: